EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library Statute and regulation checked October 28, 2026 Pharmacopeial and FDA texts Peer-reviewed

Routes and dosage forms

The route decides whether a plant-based product can be a U.S. dietary supplement and whether its contents meet the liver before the rest of the body. The format decides how it is made, which compendial tests apply and how it fails on the shelf.

6forms named in the supplement definition: tablet, capsule, powder, softgel, gelcap, liquid (21 U.S.C. 350(c)(1)(B)(i))
16 of 18units must disintegrate when 1 or 2 of the first 6 fail (harmonized disintegration test)
13–16%equilibrium water in gelatin hard-capsule shells, against 2–7% in HPMC shells
22 of 25melatonin gummy products inaccurately labeled; one had none detectable, the measured range was 74–347% of the declared amount (JAMA 2023)

Cornell LII, 21 U.S.C. 350; PDG sign-off Q-02 Disintegration, Revision 2 (June 2025); Al-Tabakha MM. J Pharm Pharm Sci 2010;13(3):428–442; Cohen PA et al. JAMA 2023;329(16):1401–1402.

Three-dimensional rendering of seven oral dosage forms in a row: a tablet, a hard capsule, a softgel, a gummy, a powder stick pack, a dropper bottle and an oral film.
  1. 1 Tablet
  2. 2 Hard capsule
  3. 3 Softgel
  4. 4 Gummy
  5. 5 Powder stick pack
  6. 6 Liquid with dropper
  7. 7 Oral film

Common oral dosage forms, rendered by EUTECNIQ; generic shapes, not to scale with each other.

Absorption paths

The route sets the first pass

A swallowed dose is absorbed in the gut and reaches the liver through the portal vein, so the gut wall and the liver can metabolize it before the rest of the body sees it. Oral mucosa, skin, lungs and nose drain to systemic veins instead. The rectum is split: the superior rectal vein drains to the portal vein, the middle and inferior rectal veins to the inferior vena cava.

When metabolism sites act in series, bioavailability is the product of the fractions that escape each one: F = Fa × FG × FH. The ADME and PBPK page treats each factor.

Only swallowed doses and the upper rectum pass the liver first; every other route reaches the systemic circulation directlyPeer-reviewed physiology
Seven absorption paths: where each dosage-form route releases its contents, where the absorbed fraction drains, and whether it passes the liver before reaching the systemic circulationRoute and formatsContents released and absorbed atAbsorbed fraction drains toLiver before the body?BodyOral, swallowedTablets, caplets, capsules,softgels, gummies, powders,liquids, shotsStomach and smallintestinePortal vein to the liverLiver firstGut wall and liver canmetabolize before thesystemic circulationSublingual and buccalFilms, sprays, sublingualtablets, lozenges, pouchesOral mucosa: sublingualepithelium 100–200 µm,buccal 500–800 µmVeins of the mouth, directlyto the systemic circulationBypasses, ifabsorbed thereThe part swallowedwith saliva follows theoral routeTransdermalPatches; topicals act mostly inlocal tissueSkin: stratum corneum,then dermal capillariesSystemic veinsBypasses liverSuits small, lipophilic,low-dose moleculesInhaledAerosols, dry powders, vaporAirways and alveoliPulmonary circulation, thenthe heartBypasses liverThe lungs canthemselves metabolizeNasalSprays, drops, gelsNasal mucosaSystemic veinsBypasses liverMetabolism on themucosal surfacelowers availabilityRectal, upper rectumSuppositories, enemasUpper rectal mucosaSuperior rectal vein to theportal veinLiver firstLike the oral routeRectal, lower rectumSuppositories, enemasLower rectal mucosaMiddle and inferior rectalveins to the inferior venacavaPartly bypassesVeins connect throughanastomoses, so thesplit variesSystemiccirculationLiver first (hepatic first pass)Partly bypassesBypasses the liverSchematicSeven absorption paths: where each dosage-form route releases its contents, where the absorbed fraction drains, and whether it passes the liver before reaching the systemic circulationOral, swallowedTablets, caplets, capsules, softgels, gummies, powders,liquids, shotsAbsorbed atStomach and small intestine; drains to portal vein to theliverLiver firstGut wall and liver can metabolize before the systemiccirculationSublingual and buccalFilms, sprays, sublingual tablets, lozenges, pouchesAbsorbed atOral mucosa: sublingual epithelium 100–200 µm, buccal500–800 µm; drains to veins of the mouth, directly to thesystemic circulationBypasses, if absorbed thereThe part swallowed with saliva follows the oral routeTransdermalPatches; topicals act mostly in local tissueAbsorbed atSkin: stratum corneum, then dermal capillaries; drains tosystemic veinsBypasses liverSuits small, lipophilic, low-dose moleculesInhaledAerosols, dry powders, vaporAbsorbed atAirways and alveoli; drains to pulmonary circulation, thenthe heartBypasses liverThe lungs can themselves metabolizeNasalSprays, drops, gelsAbsorbed atNasal mucosa; drains to systemic veinsBypasses liverMetabolism on the mucosal surface lowers availabilityRectal, upper rectumSuppositories, enemasAbsorbed atUpper rectal mucosa; drains to superior rectal vein to theportal veinLiver firstLike the oral routeRectal, lower rectumSuppositories, enemasAbsorbed atLower rectal mucosa; drains to middle and inferior rectalveins to the inferior vena cavaPartly bypassesVeins connect through anastomoses, so the split variesSchematic. Colors: rose, liver first; amber, partly; teal,bypasses.
Pond SM, Tozer TN. Clin Pharmacokinet 1984;9(1):1–25. Hua S. Front Pharmacol 2019;10:1196. de Boer AG et al. Clin Pharmacokinet 1982;7(4):285–311. Zhang H, Zhang J, Streisand JB. Clin Pharmacokinet 2002;41(9):661–680. Bahraminejad S, Almoazen H. Pharmaceutics 2025;17(8):1073. Jacob S et al. Pharmaceutics 2023;15(12):2753. Prausnitz MR, Langer R. Nat Biotechnol 2008;26(11):1261–1268. He X et al. J Control Release 2025;388:114296. Tai J et al. Pharmaceutics 2022;14(5):1073. Schematic.
Measured or reviewed evidence for each route's path into the body
RouteWhat the primary record showsSource
Oral, swallowedThe liver is usually the main first-pass site; the gut wall, blood, lungs and vascular endothelium can add to it. Extensive first pass rules some drugs out of oral use (lidocaine, naloxone, glyceryl trinitrate).Pond and Tozer 1984
Oral transmucosalFentanyl from a transmucosal lozenge (15 µg/kg, 12 volunteers): systemic bioavailability 0.52 versus 0.32 for the same dose swallowed as a solution; peak plasma at 22 versus 101 min.Streisand et al. 1991
Sublingual and buccalSublingual epithelium is 100–200 µm thick; the buccal stratified squamous epithelium is 500–800 µm.Bahraminejad and Almoazen 2025
TransdermalSuccessful transdermal drugs have molecular masses up to a few hundred daltons, partition strongly into lipids and need doses of milligrams per day or less.Prausnitz and Langer 2008
InhaledRapid absorption and avoidance of hepatic first-pass effects; deposition depends on breathing pattern and aerosol properties.He et al. 2025
NasalAvoids the hepatic first pass, but metabolism on the mucosal surface can keep bioavailability low.Tai et al. 2022
RectalHepatic first pass of high-clearance drugs such as lidocaine is partly avoided; absorption from suppositories depends heavily on the base and additives.de Boer et al. 1982

Streisand JB et al. Anesthesiology 1991;75(2):223–229. Other sources as in the figure.

United States

U.S. status by route

A dietary supplement must be “intended for ingestion” (21 U.S.C. 321(ff)(2)(A)). The statute names six forms; any other ingested form qualifies only if it “is not represented as conventional food” and not as a sole item of a meal or the diet (21 U.S.C. 350(c)(1)(B)). FDA's warning letters treat products that enter “directly through the skin or mucosal tissues” as outside the category. The final call on a product belongs to counsel.

U.S. regulatory status of each route and format for botanical products
Route or formatCan it be a dietary supplement?Basis
Tablets, capsules, softgels, gelcaps, powders, liquids (swallowed)YesNamed forms, 21 U.S.C. 350(c)(1)(B)(i) Statute
Gummies, chews and other ingested formsYes, if not represented as a conventional food or a sole item of a meal or the diet21 U.S.C. 350(c)(1)(B)(ii); 321(ff)(2)(B) Statute
Liquids, tonics and shotsSupplement or beverage, decided by name, packaging, serving size, recommended daily intake and statements such as “refresh” or “rehydrate”FDA guidance, January 2014 (docket FDA-2009-D-0542) Guidance
Sublingual tablets, films and spraysNo: “not dietary supplements and are not foods”FDA warning letter to DK Vitamins, February 5, 2019 Warning letter
Transdermal and topical productsNo: products “such as transdermal products, are not dietary supplements”; topicals are cosmetics or drugs by intended useFDA warning-letter language quoted by RAPS, June 2013; 21 U.S.C. 321(i) Warning letters
Inhaled productsNo; FDA: “Caffeine is not normally inhaled into the lungs and the safety of doing so has not been well studied”FDA warning letter to Breathable Foods (2012), as quoted by RAPS Warning letter
Nasal productsRegulable as drugs: the court held FDA may regulate a nasal vitamin B12 gel as a drug “whether or not” it is a dietary supplementUnited States v. Nature's Bounty, 72 F.3d 285 (2d Cir. 1995) Case law
Rectal productsFall within FDA's “mucosal tissues” wording; no FDA letter on a rectal supplement was located for this pageWarning-letter language above Interpretation
Buccal lozenges and oral pouchesDepends on where the contents are intended to be absorbed: swallowed, or taken up through the oral mucosaIntended use Depends on use

Cornell LII, 21 U.S.C. 321 and 350 (accessed October 27, 2026). FDA, Guidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages (January 2014). FDA warning letter 566205, DK Vitamins (February 5, 2019). Gaffney A. Regulatory Focus (RAPS), June 6, 2013. United States v. Nature's Bounty, Inc., 72 F.3d 285 (2d Cir. 1995). Legal classification is fact-specific; see legal status and claims.

Matrix

Format by route, test and risk

Sixteen formats on one sheet: the route each uses, its U.S. supplement status, how it is made, which tests carry the weight and what usually fails first. Bracketed numbers are sources; unbracketed cells are general manufacturing practice, not data.

Sixteen dosage formats by route, U.S. supplement eligibility, manufacturing process, key tests and typical stability risks
FormatRouteU.S. supplement?How it is madeKey testsTypical stability risks
TabletsOralYes [1]Direct compression, or wet granulation (binder liquid, drying) or dry granulation (roller compaction or slugging), then compression; often film-coated in a rotating pan [2, 3]Disintegration and dissolution <2040> where a monograph applies; weight variation <2091>; hardness, friability, assay [4, 5]Hardness drift and slower disintegration with age and moisture; coating cracks without enough plasticizer [3]
CapletsOralYes [1]As tablets, with an elongated, capsule-shaped punchAs tablets [4, 5]As tablets
Hard capsules, gelatinOralYes [1]Shells dip-molded: pins at 22 °C dipped in gelatin at 45–55 °C, dried, stripped, cut; filled with powder or granules and closed [6] (also: 'Dip-molded HPMC', 'deposit hot into molds', 'cooking and molding', 'Mold starch')Disintegration <2040>; weight variation <2091>; two-tier dissolution with enzymes if pellicles form [4, 7]Shell water 13–16%; brittle below about 10% RH; cross-linking with aldehydes or heat and humidity [6]
Hard capsules, HPMCOralYes [1]Dip-molded HPMC with a gelling aid (carrageenan with potassium chloride, or gellan gum) [6]As gelatin capsules; check media with potassium ions, which slow carrageenan-gelled shells [6]Shell water 2–7%; no gelatin-type cross-linking; slower opening in water at 37 °C (about 4 versus 1 min in one study) [6]
SoftgelsOralYes [1]Rotary die: two cast gelatin ribbons pass between counter-rotating die rolls; a heated wedge doses the fill; sealed at 37–40 °C; rotary-dried, then tray-dried [8]Rupture test (<2040>: Apparatus 2, 50 rpm, 500 mL, 15 min) or disintegration; dissolution with enzymes for cross-linked shells [10]Fill–shell migration; oxidation of the fill; cross-linking slows rupture [8, 10]
GummiesOralYes, if not represented as a conventional food [1]Cook a gelatin or pectin gel with sugars and syrups (up to 75% sugar solids), deposit hot into molds, cure at about 45 °C for up to 72 h [9, 11]Assay per unit and content uniformity; water activity; no USP disintegration requirement located for gummiesMoisture gain or loss, sugar crystallization, heat softening of gelatin [9]; active loss in cooking
Powders and sachetsOralYes [1]Blending; spray-dried or agglomerated ingredients for wetting; filled into stick packs or tubsFill weight, blend uniformity, assay, moisture, microbial limitsCaking from moisture, oxidation, color change
LiquidsOralYes, unless represented as a beverage [1, 12]Dissolving or emulsifying the active; preservative system; pH set; filled into bottles or dropper vialsAssay, pH, microbial limits, preservative content, appearanceHydrolysis and oxidation in solution, sedimentation or creaming, microbial growth
Tonics and shotsOralDepends on name, packaging, serving size and claims [12]As liquids, in single-serve unitsAs liquidsAs liquids; headspace oxygen in small fills
Sublingual tabletsSublingualNo [13]Compression of rapidly disintegrating blendsUSP <701> carries a separate national procedure for sublingual tablets [5]Moisture uptake by fast-disintegrating excipients
Sublingual filmsSublingual or buccalNo [13]Solvent casting (a polymer solution with plasticizer and active, cast and dried) or hot-melt extrusion [14, 15]Thickness, content uniformity, disintegration time; no official pharmacopeial disintegration method for these films [14]Residual solvent, brittleness or tack with humidity, uneven drug distribution from air bubbles or casting viscosity [15]
Sublingual spraysSublingual or buccalNo [13]Solution or emulsion in a metered pumpDelivered dose per actuation, droplet size, assay, microbial limitsDegradation in solution; pump and container interactions
LozengesBuccal, then swallowedDepends on intended absorption siteCompression, or cooking and molding a sugar or polyol massAssay per unit, weight, dissolution time in the mouth (method set by the maker)Moisture uptake, sugar crystallization
Oral pouchesBuccal (between lip and gum)Depends on intended absorption sitePowder or fiber filling sealed into a porous nonwoven pouchFill weight, assay, moistureMoisture loss or gain; flavor loss
Transdermal patchesTransdermalNo [16]Matrix: drug-in-adhesive coated from solvent, hydrogel or hot melt, dried, laminated to backing and release liner, die-cut; reservoir: gel heat-sealed between backing and a microporous membrane [17]Peel adhesion, tack, release-liner peel, shear, cold flow, in vitro release, residual solvents, crystal presence [17]Drug crystallization in the matrix, loss of adhesion, cold flow [17]
Topicals (creams, gels, lotions)Topical, mostly localNo; cosmetic or drug by intended use [16, 18]Emulsification or gelling, homogenization, fillingViscosity, pH, assay, microbial limits, preservative efficacyPhase separation, microbial growth, oxidation

[1] 21 U.S.C. 321(ff), 350(c)(1)(B). [2] Shanmugam S. Bioimpacts 2015;5(1):55–63. [3] Seo KS et al. Pharmaceutics 2020;12(9):853. [4] USP–NF <2040> scope (USP DOI page); 21 U.S.C. 343(s)(2). [5] PDG sign-off Q-02 Disintegration, Rev. 2 (June 2025), USP local requirements. [6] Al-Tabakha MM. J Pharm Pharm Sci 2010;13(3):428–442. [7] FDA, Dissolution Testing of Immediate Release Solid Oral Dosage Forms (August 1997). [8] Naharros-Molinero A et al. Adv Healthc Mater 2024;13(1):e2302250. [9] Vásquez-Senador M et al. Gels 2026;12(9):841. [10] Damian F et al. Pharmaceutics 2021;13(2):214. [11] Pournemati N et al. J Texture Stud 2026;57(5):e70117. [12] FDA liquids and beverages guidance (January 2014). [13] FDA warning letter to DK Vitamins (2019). [14] Salawi A. Pharmaceuticals 2022;15(7):844. [15] Jacob S et al. Pharmaceutics 2023;15(12):2753. [16] FDA warning-letter language quoted by RAPS (2013). [17] FDA draft guidance, Transdermal and Topical Delivery Systems (November 2019). [18] 21 U.S.C. 321(i).

Sixteen formats by route: which can be a U.S. supplement, and what usually fails firstSchematic · content from this page
Option grid. Bands for oral, sublingual or buccal, and skin routes. Each format shows whether it can be a U.S. dietary supplement (yes, conditional or not a supplement) and its typical stability risk.
Summarized from the matrix below (its sources [1]–[18]); risks shortened from its last column. Drawn by EUTECNIQ. Full-size SVG
Tablets and capsules

Tablets and hard capsules

Granulation turns fine powder into free-flowing granules that compress evenly; it is wet when a binder liquid is used and dry when roller compaction or slugging does the work. Film coats are polymer solutions or suspensions with plasticizers and pigments, sprayed onto a rotating bed of tablets and dried with hot air. A capsule replaces compression with a shell, so the shell's water and chemistry become the weak point.

Gelatin and HPMC hard-capsule shells compared
PropertyGelatin shellHPMC shell
Equilibrium water13–16% at 35–65% RH; about 14% at 50% RH2–7% at 10–60% RH; about 6% at 50% RH
Low humidityBrittle below about 10% RHRemains flexible even at low moisture content
GellingGelatin gels on cooled pins (22 °C) from a 45–55 °C dipGels on heating, so pins run at about 70 °C; or a gelling aid: carrageenan with potassium chloride, or gellan gum
Cross-linkingOccurs with aldehydes such as formaldehyde and under heat and humidity stressNot observed under the same conditions
Opening in water, 37 °CAbout 1 minAbout 4 min (carrageenan-gelled shells, one study)
Temperature and pHGenerally does not dissolve below 30 °COpened more slowly than gelatin in tests at 37 °C and above, notably in pH 6.8 phosphate buffer
Medium effectsPellicles from cross-linking; enzymes added in a second tierPotassium ions slow release from carrageenan-gelled shells

Al-Tabakha MM. HPMC capsules: current status and future prospects. J Pharm Pharm Sci 2010;13(3):428–442 (reviewing the primary studies). Granulation: Shanmugam S. Bioimpacts 2015;5(1):55–63. Film coating: Seo KS et al. Pharmaceutics 2020;12(9):853.

Two measured findings on capsule quality
FindingResultSource
Cross-linked gelatin capsules in peopleCapsules stressed with formaldehyde until they failed dissolution without enzymes ruptured later in vivo (about 71 min for the most cross-linked, fed), yet each was bioequivalent to the control by AUC and Cmax (10 subjects, six-way design). Two-tier dissolution with gastric or intestinal enzymes predicted in vivo performance.Digenis GA et al. Pharm Res 2000;17:572–582
Fill weight of a botanical capsuleOf 52 Andrographis capsule products, 24 (46%) had powder weights more than 10% from the label; 29 (56%) met all five pharmacopeial methods compared.Wattananat T et al. J Thai Tradit Altern Med 2019;17(3):390–402
Four oral forms hold the dose in four ways: a compressed, coated core; a two-piece shell; a sealed liquid fill; a sugar gelSchematic; values from cited sources
Four schematic cross-sections. A: a film-coated tablet with a compressed granular core, a thin sub-coat and an outer film coat, plus the outline of a caplet. B: a two-piece hard capsule, the cap telescoped over the body around a powder fill, with the equilibrium water content of gelatin and HPMC shells. C: a softgel, an oil fill inside a plasticized gelatin shell joined at a seam, beside a rotary-die encapsulator in which two ribbons pass between counter-rotating die rolls while a heated wedge doses the fill. D: a gummy piece and a magnified view of its gel network, with junction zones, dissolved sugars and a dispersed active.
Schematic cross-sections, not to scale. Film coating: Seo KS et al. Pharmaceutics 2020;12:853. Capsule shells: Al-Tabakha MM. J Pharm Pharm Sci 2010;13(3):428–442. Softgel shell and rotary die: Naharros-Molinero A et al. Adv Healthc Mater 2024;13:e2302250. Gummies: Pournemati N et al. J Texture Stud 2026;57:e70117; Vásquez-Senador M et al. Gels 2026;12:841. Illustration by EUTECNIQ. Full-size SVG
Softgels

Softgels

A softgel holds a liquid fill, oil or suspension, in a plasticized gelatin shell. The rotary die forms, fills and seals in one step, and the shell then loses most of its water in drying. Gullapalli calls the softgel a “very dynamic” dosage form whose stability over shelf life is hard to secure; the rupture test and enzyme-assisted dissolution exist for that reason.

Softgel process and test values from primary and review sources
Stage or testValueSource
Shell formulaGelatin typically 40–45% of the wet shell mass; plasticizers glycerol or sorbitol; shell mass flows at about 60 °CNaharros-Molinero 2024
Ribbon castingCast on air-cooled drums at 13–14 °C; ribbon 0.022–0.045 in, most 0.025–0.032 in, controlled to ±0.1 mmNaharros-Molinero 2024
SealingWedge doses the fill between counter-rotating die rolls; seals at 37–40 °CNaharros-Molinero 2024
DryingShell water 30–40% w/w after encapsulation; rotary drying 1–3 h with air below 35 °C, then tray drying at 21–24 °C and 20–30% RH for hours to days, to an equilibrium 4–10% w/wNaharros-Molinero 2024
Storage15–30 °C and not more than 50% RH recommendedNaharros-Molinero 2024
Material lossGelatin waste in the rotary die can reach 50% of the gelatin usedNaharros-Molinero 2024
Rupture test (<2040>, as quoted)Apparatus 2, 50 rpm, 500 mL, 15 min; all units rupture within 15 min, or, on retest of 12 more, no more than 2 of 18 take 15–30 minDamian et al. 2021
Second-tier enzymes (<711>, as quoted)Pepsin below pH 4; papain or bromelain at pH 4–6.8 (≤ 550,000 units/1000 mL); pancreatin above pH 6.8 (≤ 2000 protease units/1000 mL)Damian et al. 2021
Rupture versus disintegrationVitamin softgels stored 2 and 4 weeks at 40 °C/75% RH passed conventional disintegration but failed the rupture test, while their gelatin dissolved completely by 60 min; the authors judged the methods not equivalentYacobucci et al. 2014

Naharros-Molinero A et al. Shell formulation in soft gelatin capsules. Adv Healthc Mater 2024;13(1):e2302250. Damian F et al. Challenges of dissolution methods development for soft gelatin capsules. Pharmaceutics 2021;13(2):214 (quoting USP <2040> and <711>). Yacobucci M et al. Am J Pharm Educ 2014;78(5):Article 111 (meeting abstract). Gullapalli RP. J Pharm Sci 2010;99(10):4107–4148. Kaliyamoorthy S. Pharm Dev Technol 2026;31(7):1217–1231 (die-roll designs).

Gummies

Gummies

A gummy is a sugar-rich hydrogel. Gelatin gels are thermoreversible and can melt in warm storage; high-methoxyl pectin gels under acid with high sugar, low-methoxyl pectin through calcium bridges. Sugars and syrups bind water and slow syneresis. Cooking heat, acid and long curing are the steps an active must survive, and the measured label accuracy of gummies shows how often dosing goes wrong.

Gummy process values and measured label accuracy and bioavailability
ItemValueSource
Sugar solidsUp to 75% in gummies and jelly candyPournemati et al. 2026
Depositing and curingHot depositing; extended curing at about 45 °C for up to 72 hPournemati et al. 2026
Mold starchNative corn starch pre-dried to 5–7% moisture forms the cavities and absorbs surface moisture; it is not part of the finished piecePournemati et al. 2026
Gelatin networkChains form triple helices below about 35 °C; the gel melts near body temperatureNaharros-Molinero 2024
Label accuracy25 melatonin gummy products: 22 (88%) inaccurately labeled; melatonin 74–347% of label; 3 (12%) within ±10%; one had none detectableCohen et al. 2023
Gummy versus capletVitamin C 1000 mg, 30 adults, crossover: no significant difference in plasma AUC0–24h or Tmax; caplet Cmax slightly higher (study funded by the gummy's maker)Evans et al. 2020

Pournemati N et al. J Texture Stud 2026;57(5):e70117. Naharros-Molinero A et al. Adv Healthc Mater 2024;13(1):e2302250. Vásquez-Senador M et al. Gels 2026;12(9):841. Cohen PA et al. JAMA 2023;329(16):1401–1402. Evans M et al. J Am Coll Nutr 2020;39(5):422–431.

Powders and liquids

Powders, liquids and shots

Powders and liquids carry larger doses than a capsule can hold, but a liquid can stop being a supplement on the strength of how it is sold. FDA's 2014 guidance treats beverages as conventional foods and lists the factors that decide which side of the line a liquid sits on; usually a combination of them, sometimes the name alone.

Factors FDA uses to decide whether a liquid is represented as a beverage
FactorWhat FDA describes
Product or brand nameConventional-food terms such as “beverage,” “drink,” “water” or “soda” represent the product as a conventional food; in some cases the name alone may suffice
PackagingSize, shape, color and design of the container, the volume it holds, whether it is reclosable or single-serve, and its similarity to common beverage packaging
Serving size and daily intakeFDA estimates average daily drinking-fluid intake at about 1.2 L; directions that supply all or a large part of it (for example, “Drink up to three 16-ounce bottles per day”) represent the product as a conventional food
Statements and graphicsClaims to “refresh” or “rehydrate,” and serving suggestions or vignettes, can make a product with a Supplement Facts panel a conventional food
Use as a beverageA product that in practice replaces ordinary sources of drinking fluid is generally considered a conventional food, even without saying so

FDA. Guidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages. January 2014; docket FDA-2009-D-0542; Section III.A.

Compendial tests

Which tests apply

USP's dietary-supplement chapters apply where a monograph cites them, and the statute gives them teeth: a supplement covered by a compendium, represented as meeting it and failing is misbranded, and one outside any compendium is misbranded if it fails the quality specifications, “including tablet or capsule disintegration,” that it claims (21 U.S.C. 343(s)(2)). Every manufacturer must set finished-batch specifications for identity, purity, strength and composition (21 CFR 111.70(e)).

USP general chapters relevant to dosage forms and what of each is publicly verifiable
ChapterCoversPublicly verifiable content
<701> DisintegrationTablets and capsules (drug products)Harmonized text (PDG Q-02, Rev. 2, June 2025): basket-rack in fluid at 37 ± 2 °C, 29–32 cycles/min over 53–57 mm; 6 units; if 1 or 2 fail, test 12 more, and at least 16 of 18 must disintegrate. The time limit comes from the monograph. USP adds national procedures for delayed-release, buccal, sublingual, chewable and orally disintegrating tablets.
<711> DissolutionSolid oral dosage formsHarmonized and declared interchangeable (ICH Q4B Annex 7(R2)). FDA's 1997 guidance: 37 ± 0.5 °C; 500, 900 or 1000 mL; basket 50–100 rpm, paddle 50–75 rpm; pepsin or pancreatin may be needed to dissolve gelatin pellicles.
<905> Uniformity of dosage unitsDrug productsHarmonized (ICH Q4B Annex 6): acceptance value AV = |M − X̄| + ks, k = 2.4 for 10 units and 2.0 for 30; L1 = 15.0, L2 = 25.0. Weight variation may replace content uniformity only at or above 25 mg and 25%.
<2040> Disintegration and dissolution of dietary supplementsDietary supplements, “where stated in the individual monographs”Scope on USP's DOI page. Rupture test for softgels as quoted in peer-reviewed literature (section 5). Full text is by subscription.
<2091> Weight variation of dietary supplementsDietary supplementsTitle and existence only; the acceptance limits are in the subscription text and are not reproduced here.

Cornell LII, 21 U.S.C. 343(s)(2)(D)–(E). eCFR, 21 CFR 111.70(e), up to date as of October 23, 2026. PDG sign-off document Q-02 Disintegration, Revision 2, June 2025 (PMDA). ICH Q4B Annex 7(R2), November 2010, and Annex 6, November 2013. Japanese Pharmacopoeia 6.02, Uniformity of Dosage Units, harmonized text (PMDA). FDA, Dissolution Testing of Immediate Release Solid Oral Dosage Forms, August 1997. USP–NF <2040> (DOI 10.31003/USPNF_M99970_04_01), introduction.

On target, ten units pass up to a standard deviation of 6.25% of label; at a mean of 92% the room shrinks to 3.54%Computed from the harmonized formula
Acceptance value of the harmonized content-uniformity test for 10 units against their standard deviation, for four batch means; the test passes at 15.0 or belowAcceptance value (AV) for the first 10 units, n = 10, k = 2.40510152025012345678Standard deviation of the 10 results, s (% of label claim)Mean 100%Mean 97%Mean 95%Mean 92%L1 = 15.0: pass at or belowMean 100%: largest passing s = 6.25Mean 97%: largest passing s = 5.63Mean 95%: largest passing s = 4.79Mean 92%: largest passing s = 3.54Largest standard deviation that still passesMean 100%s ≤ 6.25Mean 97%s ≤ 5.63Mean 95%s ≤ 4.79Mean 92%s ≤ 3.54A mean within 98.5–101.5% adds nothing (Mequals the mean); below 98.5%, each point ofshortfall uses 1 of the 15 points.If AV > 15.0, test 20 more units; all 30 must giveAV ≤ 15.0 (k = 2.0) and every unit must lie within75–125% of M.Acceptance value of the harmonized content-uniformity test for 10 units against their standard deviation, for four batch means; the test passes at 15.0 or belowAV for the first 10 units (k = 2.4)051015202502468s, % of label claimMean 100%Mean 97%Mean 95%Mean 92%L1 = 15.0Largest standard deviation that passesMean 100%s ≤ 6.25Mean 97%s ≤ 5.63Mean 95%s ≤ 4.79Mean 92%s ≤ 3.54A mean within 98.5–101.5% adds nothing (M equals themean); below 98.5%, each point of shortfall uses 1 of the 15points.If AV > 15.0, test 20 more units; all 30 must give AV ≤ 15.0 (k= 2.0) and every unit must lie within 75–125% of M.
AV = |M − X̄| + ks with k = 2.4 (n = 10), T = 100%, M = X̄ for 98.5 ≤ X̄ ≤ 101.5% and M = 98.5% below that; L1 = 15.0. Harmonized Uniformity of Dosage Units text (JP 6.02; USP <905>; ICH Q4B Annex 6). Computed October 28, 2026.
Oral mucosa

Films, sprays, lozenges, pouches

These formats release their contents in the mouth. Absorption through the mucosa skips the portal circulation, but whatever is swallowed with saliva is absorbed in the gut like any oral dose. In the United States, sublingual products are not dietary supplements, so a sublingual film or spray of a botanical sits in the drug framework unless counsel concludes otherwise.

Oral-mucosal formats: manufacturing, key attributes and evidence
FormatProcess and key attributesEvidence
Orodispersible and sublingual filmsSolvent casting and hot-melt extrusion are the most common methods; fast-dissolving films are about 50–150 µm thick and dissolve within 30 s; films of 2 × 2 cm and up to 100 µm are considered acceptable in the mouthSalawi 2022; Jacob et al. 2023
Film disintegration testingNo official pharmacopeial method; laboratories use Petri-dish or slide-frame methods, with typical times of 5–30 sSalawi 2022
Buccal spray, vitamin D3Systematic review: 4 randomized trials (800–3000 IU/day, 30 days to 3 months); only one, with limitations, favored the spray; buccal spray did not appear superior to other formsGrammatikopoulou et al. 2020
Transmucosal lozenge, fentanylBioavailability 0.52 versus 0.32 for the swallowed solution; faster peak (22 versus 101 min)Streisand et al. 1991
Buccal lozenges and pouchesRegulatory status follows the intended absorption site: swallowed contents, or uptake through the mucosaInterpretation of 21 U.S.C. 321(ff)(2)(A) and the FDA warning letter to DK Vitamins (February 5, 2019)

Salawi A. Pharmaceuticals 2022;15(7):844. Jacob S et al. Pharmaceutics 2023;15(12):2753. Grammatikopoulou MG et al. Nutrients 2020;12(3):691. Streisand JB et al. Anesthesiology 1991;75(2):223–229. FDA warning letter to DK Vitamins, February 5, 2019.

A sublingual film crosses 100–200 µm of epithelium to reach capillaries that bypass the portal vein; what is swallowed takes the oral routeSchematic; thicknesses to scale
Schematic cross-section under the tongue: a thin film lies on a layer of saliva over the stratified sublingual epithelium, above the lamina propria with capillaries. Dissolved active diffuses through the epithelium into the capillaries and drains to the systemic circulation; the part swallowed with saliva follows the oral route. A to-scale bar chart compares film thickness (50 to 150 micrometers for fast-dissolving films) with sublingual (100 to 200) and buccal (500 to 800) epithelial thickness.
Schematic section; the bar chart is to scale. Film thickness: Salawi A. Pharmaceuticals 2022;15:844. Epithelium: Bahraminejad S, Almoazen H. Pharmaceutics 2025;17:1073. Direct systemic entry: Zhang H et al. Clin Pharmacokinet 2002;41:661–680. Swallowed fraction: Jacob S et al. Pharmaceutics 2023;15:2753. Illustration by EUTECNIQ. Full-size SVG
Skin

Patches and topicals

FDA describes two transdermal designs: a matrix with the active dissolved or partly suspended in adhesive, and a reservoir with an active gel heat-sealed between the backing and a microporous membrane. Because reservoir systems carry inherent failure modes, FDA recommends developers focus on matrix designs. Transdermal and topical delivery systems are combination products under 21 CFR part 3; creams, gels and lotions without a carrier device are not delivery systems in this sense.

Transdermal system layers, their function and the quality attributes FDA lists
LayerFunctionAttributes FDA lists
Backing membraneOuter layer; carries the labelExtractables and leachables; label legibility
Drug-in-adhesive matrix or gel reservoirHolds the active with adhesives, permeation enhancers, softeners and preservativesAssay, uniformity of dosage units, enhancer content, impurities, absence of visible crystals, residual drug
Rate-controlling membrane (reservoir type)Microporous layer that meters release from the gelIn vitro release profile
AdhesiveHolds the system on skin for the wear periodPeel adhesion, tack, shear strength, cold flow, residual solvents and monomers
Release linerProtects the adhesive until useRelease-liner peel strength

FDA. Transdermal and Topical Delivery Systems: Product Development and Quality Considerations. Draft guidance, November 2019, Sections II–III (draft, not for implementation). Status as a non-supplement: FDA warning-letter language quoted by RAPS (2013).

A matrix patch carries the active in its adhesive; a reservoir patch meters a sealed gel through a microporous membraneAfter FDA draft guidance, 2019
Two schematic cross-sections of transdermal systems as FDA describes them. Left, matrix type: a backing membrane over a drug-in-adhesive matrix, with a release liner being peeled away before use. Right, reservoir type: a backing membrane and a microporous rate-controlling membrane heat-sealed around a drug gel reservoir, an adhesive layer and a release liner. Below both, skin: stratum corneum, viable epidermis and dermis with capillaries.
Schematic, not to scale, after Figures 1–2 of FDA draft guidance, Transdermal and Topical Delivery Systems: Product Development and Quality Considerations (November 2019; draft, not for implementation). Illustration by EUTECNIQ. Full-size SVG
Proposed

Where EUTECNIQ would work

Proposed EUTECNIQ would fix the route and the U.S. category before formulation starts, then design the format against its weak point: shell water for capsules, fill–shell exchange for softgels, heat and moisture for gummies. It would plan disintegration, dissolution and uniformity work by external or future in-house laboratories. It has no laboratory, products or results today.

Related: Delivery technologies · ADME and PBPK · Legal status and claims · Dietary supplements · Cosmetics and MoCRA

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.